Health Bulletin 24/January/2022

Published On 2022-01-24 12:05 GMT   |   Update On 2022-01-24 12:05 GMT
Advertisement

Here are Top Health stories of the day


Delhi: Cases dip, govt to bring up easing restrictions with L-G


Pay annual DNB course fee directly to NBE: Natboard tells NEET PG candidates

Through a recent notice, the National Board of Examinations (NBE) has informed about the payment of First-year course fee at the time of joining Diploma/ DNB seat at NBEMS Accredited Hospital.

The counseling for admission to Diploma and DNB Courses of NBEMS for admission session 2021 is being conducted by the Medical Counseling Committee (MCC) of DGHS, Govt. of India along with the counseling for MD/MS/PG Diploma seats.

Advertisement

For more details, check out the full story on the link below:

Pay Annual DNB Course Fee Directly To NBE: Natboard Tells NEET PG candidates


Patient not given treatment, 5 day delay in COVID-19 report: Hospital told to pay Rs 5 lakh compensation

Bengal-based Jagannath Gupta Institute of Medical Sciences and Hospital in Budge Budge has been ordered to pay a compensation of Rs 5 Lakh to the patient's family for keeping the patient in the hospital without providing him treatment. The order was issued by West Bengal Clinical Establishment Regulatory Commission (WBCERC) on Friday.

The family members of the patient alleged that the patient was 'driven out and 'turned down' by the hospital when his COVID positive reports arrived after almost 5 days.

For more information, check out the full story on the link below:

Patient Not Given Treatment, 5 Day Delay In COVID-19 Report: Hospital Told To Pay Rs 5 Lakh Compensation


Apple, Mylan lose US SC bids to challenge patent review rule

The U.S. Supreme Court on Tuesday turned back challenges by Apple Inc and drugmaker Mylan Laboratories Ltd to a rule change that made it harder to contest patents before the U.S. Patent and Trademark Office.

The internal rule, adopted in 2020 under former PTO director Andrei Iancu, gives judges at the agency's Patent Trial and Appeal Board greater discretion to reject challenges to the validity of specific patents.

For more information, check out the full story on the link below:

Apple, Mylan lose US SC bids to challenge patent review rule  


Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News